Massachusetts Governor Proposes $1B Stem-Cell Plan
Governor Deval Patrick of Massachusetts has proposed a plan for committing $1-billion over the next decade to life-sciences research, including the creation of a stem-cell bank, in an effort to make the state a global leader in biotechnology.
Governor Deval Patrick of Massachusetts has proposed a plan for committing $1-billion over the next decade to life-sciences research, including the creation of a stem-cell bank, in an effort to make the state a global leader in biotechnology.
The plan, outlined during a speech at the BIO 2007 convention held at Boston, includes a 10-year, $1 billion investment package to ensure the state’s ability to support life sciences progress “from the idea stage through the production stage.”
The initiative calls for the creation of a stem-cell bank that will serve a centralized repository of stem-cell lines for public and private research. Boston University, Brigham and Women’s, Children’s Hospital, Harvard University, the Massachusetts Institute of Technology, Massachusetts General Hospital, Partners HealthCare, and the University of Massachusetts have already agreed to participate in the bank when it is completed.
Key to the Governor’s plan is new legislation to strengthen the Massachusetts Life Science Center and charge it with the execution of a life sciences mission focused on science and economic development, strategic investments at critical stages of the development cycle, and collaboration with the private sector to create innovation infrastructure critical to both researchers and companies.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
